Study of Safety and Efficacy of BCL201 and Idelalisib in Patients With FL and MCL

NCT02603445 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Follicular Lymphoma, Mantle Cell Lymphoma

Interventions

DRUG: BCL201
DRUG: Idelalisib

Sponsor

Novartis Pharmaceuticals